Visiongain Publishes Antibacterial Drugs Market Report 2020-2030

25 August 2020
Pharma

Visiongain has launched a new pharma report Antibacterial Drugs Market : Forecasts Report of  2020-2030 by Type (Cephalosporins (Rocephin, Sulperazon, Ceftin/Zinnat, Meiact, Flomox, Teflaro, Zeftera, Ceftolozane-tazobactam, Ceftazidime-Avibactam, Others), Penicillins (Generic amoxicillin, Augmentin, Zosyn/Tazocin, Unasyn, Generic Amoxicllin-clavulanic Acid, Amoxil, Others), Fluoroquinolones (Avelox, Cravit, Vigamox, Ciprodex, Cipro/Cirpobay, Geninax, Baxdela, Others), Macrolides (Biaxin/Clarith, Zithromax, Dalacin, Dificid, Solithromycin, Others), by Carbapenems (Invanz, Merrem/Meropen, Primaxin, Doribax, Others), Others (Zyvox, Cubicin, Tygacil, TOBI/TIP, Solodyn, Vibativ, Sirturo, Tedizolid, Oritavancin, Dalbavancin, Nemonoxacin, Surotomycin)), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, E-Commerce), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) and Analysis of Leading Drug Discovery Outsourcing Companies. PLUS, COVID-19 Recovery Scenarios.

This report evaluates the antibacterial drugs market for the period, 2020-2030. The global market is estimated to be worth US$xx million in 2020 and is projected to reach US$xx million in 2030 while growing at a CAGR of xx% over the forecast period from 2020 to 2030.

"The growth of the antibacterial drug market has been relatively stagnant due to generic erosion, lack of new antibacterial drugs entering the market and rising prevalence of treatment-resistant bacteria. Initiatives to regulate the consumption of antibacterial drugs in several national markets, though necessary, have also hampered the growth of this market."
Industry Analyst, Visiongain

Antibacterial drugs form one of the oldest segments of the pharmaceutical industry. More than a hundred new drugs have been launched in this market since the 1940s. However, the strong position of antibiotics is threatened. High use of generic drugs, coupled with a limited pipeline of new therapies, has affected, and will continue to threaten, growth of the antibacterial drugs market. Increasing resistance to current antibiotics is also limiting the treatment choice for healthcare providers.

Although the limited R&D pipeline for new antibacterial drugs, patent expiries and geneticization, will continue to affect the market in the early years of the forecast period 2020 to 2030, opportunities exist. Around seven novel antibacterial drugs will be launched in the next two years, including treatments targeting multidrug-resistant Gram-negative bacterial infections, where high unmet clinical needs exist worldwide.

There are pipeline candidates in this sector that have novel mechanisms of action or improve on existing classes. We discuss the merits of cephalosporin-β-lactases inhibitor combinations, and entirely novel therapeutic monoclonal antibodies targeting S. aureus and P. aeruginosa. This report identifies how industry and market trends affect the drug developers with novel antibiotic therapies, as well as generics manufacturers, and other participants in that industry and market.

Some of the major companies operating in the global antibacterial drugs market are Pfizer Inc., Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, BioVersys AG, Allecra Therapeutics GmbH, Adenium Biotech ApS, Bayer AG, Eli Lilly and Company, Johnson & Johnson Services, Inc., AstraZeneca PLC, Allergan, Melinta Therapeutics, SHIONOGI Co., Ltd., and DAIICHI SANKYO COMPANY, LIMITED among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever